Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile

Tjeerd Barf, Todd Covey, Raquel Izumi, Bas van de Kar, Michael Gulrajani, Bart van Lith, Maaike van Hoek, Edwin de Zwart, Diana Mittag, Dennis Demont, Saskia Verkaik, Fanny Krantz, Paul G. Pearson, Roger Ulrich, and Allard Kaptein

Acerta Pharma BV, Oss, The Netherlands

Received June 13, 2017; accepted August 31, 2017

ABSTRACT

Several small-molecule Bruton tyrosine kinase (BTK) inhibitors are in development for B cell malignancies and autoimmune disorders, each characterized by distinct potency and selectivity patterns. Herein we describe the pharmacologic characterization of BTK inhibitor acalabrutinib [compound 1, ACP-196 (4-[(8-amino-3-(2S)-1-but-2-ynoyl)pyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-[2-(pyridyl)benzamide)]. Acalabrutinib possesses a reactive butynamide group that binds covalently to Cys481 in BTK. Relative to the other BTK inhibitors described here, the reduced intrinsic reactivity of acalabrutinib helps to limit inhibition of off-target kinases having cysteine-mediated covalent binding potential. Acalabrutinib demonstrated higher biochemical and cellular selectivity than ibrutinib and spebrutinib (compounds 2 and 3, respectively). Importantly, off-target kinases, such as epidermal growth factor receptor (EGFR) and interleukin 2-inducible T cell kinase (ITK), were not inhibited. Determination of the inhibitory potential of anti-immunoglobulin M–induced CD69 expression in human peripheral blood mononuclear cells and whole blood demonstrated that acalabrutinib is a potent functional BTK inhibitor. In vivo evaluation in mice revealed that acalabrutinib is more potent than ibrutinib and spebrutinib. Preclinical and clinical studies showed that the level and duration of BTK occupancy correlates with in vivo efficacy. Evaluation of the pharmacokinetic properties of acalabrutinib in healthy adult volunteers demonstrated rapid absorption and fast elimination. In these healthy individuals, a single oral dose of 100 mg showed approximately 99% median target coverage at 3 and 12 hours and around 90% at 24 hours in peripheral B cells. In conclusion, acalabrutinib is a BTK inhibitor with key pharmacologic differentiators versus ibrutinib and spebrutinib and is currently being evaluated in clinical trials.

Introduction

Bruton tyrosine kinase (BTK) is a Tec-family nonreceptor protein kinase expressed in B cells, myeloid cells, mast cells, and platelets. B cell receptor (BCR)–mediated signaling is essential for activation, proliferation, and survival of B lymphocytes, and BTK is an essential component of the BCR signaling cascade (Hendriks et al., 2014). Expression of BTK in B cell leukemias and lymphomas has also been reported (de Weers et al., 1993; Katz et al., 1994). Furthermore, BTK is involved in the regulation of FcγR signaling in myeloid cells (Jongstra-Bilen et al., 2008) and in mast cell degranulation after FcεR1 activation (Ellmeier et al., 2011). These features of BTK render it a very attractive target in treating B cell malignancies (Hendriks et al., 2014) and autoimmune disease (Whang and Chang, 2014). Several small-molecule inhibitors of BTK have progressed to the clinic (Table 1) and collectively demonstrate clinical validation of BTK inhibition in B cell malignancies. Most of the BTK inhibitors listed in Table 1 have been reported to bind in a covalent fashion to a cysteine residue (Cys481) at the rim of the ATP binding pocket of BTK (Pan et al., 2007; Norman, 2016). To date, ibrutinib is the only BTK inhibitor that has received marketing authorization for the treatment of B cell malignancies (Ponader and Burger, 2014); however, it is associated with adverse events not likely due to inhibition of BTK function, based on clinical observations in patients with X-linked agammaglobulinemia who have dysfunctional BTK (Winkelstein et al., 2006). These
Ibrutinib-mediated adverse events include rash, diarrhea, arthralgias or myalgias, atrial fibrillation, and major hemorrhage (Byrd et al., 2013; Wang et al., 2013; O’Brien et al., 2014), some of which may be explained by inhibition of off-target kinases EGFR, TEC, ITK, and TXK (Honigberg et al., 2010). Spebrutinib is another covalent BTK inhibitor that was subject to clinical evaluation; although it was reportedly a highly selective inhibitor (Evans et al., 2013), doses needed to achieve a partial response in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma are higher than for ibrutinib (Brown et al., 2016).

Here we report the differentiated profile of BTK inhibitor acalabrutinib [compound 1, ACP-196 (1,4-[8-amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-(2-pyridyl)benzamide)]. Acalabrutinib is a small-molecule irreversible BTK inhibitor (Fig. 1) that shows encouraging clinical activity and safety in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (Byrd et al., 2016). The preclinical profile of acalabrutinib and a few additional compounds was compared with ibrutinib.

**Table 1**

<table>
<thead>
<tr>
<th>Compound</th>
<th>Company</th>
<th>Stage of Development</th>
<th>Primary Therapeutic Area</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acalabrutinib (ACP-196)</td>
<td>Acerta Pharma</td>
<td>Phase 3</td>
<td>Oncology</td>
<td>Byrd et al. (2016)</td>
</tr>
<tr>
<td>BGB-3111</td>
<td>Beigene</td>
<td>Phase 3</td>
<td>Oncology</td>
<td>Tam et al. (2015)</td>
</tr>
<tr>
<td>Spebrutinib (CC-292)</td>
<td>Celgene</td>
<td>Phase 2</td>
<td>Autoimmune</td>
<td>Evans et al. (2013)</td>
</tr>
<tr>
<td>Evobrutinib (M2951)</td>
<td>Merck Serono</td>
<td>Phase 2</td>
<td>Autoimmune</td>
<td>Grenningloh (2016)</td>
</tr>
<tr>
<td>PRN-1068</td>
<td>Principia</td>
<td>Phase 2</td>
<td>Autoimmune</td>
<td>Smith et al. (2015)</td>
</tr>
<tr>
<td>LY337641 (HM-71224)</td>
<td>Lilly</td>
<td>Phase 2</td>
<td>Autoimmune</td>
<td>Park et al. (2016)</td>
</tr>
<tr>
<td>M7583</td>
<td>Merck Serono</td>
<td>Phase 1/2</td>
<td>Oncology</td>
<td>Bender et al. (2016)</td>
</tr>
<tr>
<td>Tirabrutinib (GS-4059)</td>
<td>Gilead</td>
<td>Phase 1</td>
<td>Oncology</td>
<td>Walter et al. (2016)</td>
</tr>
<tr>
<td>AC-0058TA</td>
<td>ACEA Biosciences</td>
<td>Phase 1</td>
<td>Autoimmune</td>
<td>—</td>
</tr>
</tbody>
</table>

*Development stage of most advanced clinical program, based on ClinicalTrials.gov. Additional potential covalent BTK inhibitors include CT-1530, BMS-986195, and DTRMWXHS-12.*

---

**Fig. 1.** (Left) Chemical structures of clinical irreversible binding BTK inhibitors. (Top right) Front view of a binding model of acalabrutinib (gold) in the ATP binding pocket of BTK. (Bottom right) Second view of the model, showing the hydrogen bonding interaction of the 2-pyridylamide moiety with Ser538 and Asp539.
(PCI-32765, compound 2) and spebrutinib (CC-292, compound 3) to investigate potential differences in potency, efficacy, and selectivity, while also engaging in covalent binding. Comparative preclinical studies involved pharmacologic profiling in biochemical and functional cellular assays, as well as in a PD model in mice. BTK target occupancy was correlated with PD markers by using a potent and selective biotinylated probe that was developed based on the chemical structure of acalabrutinib. In addition, we aimed to better understand the potential risk of adverse events by investigating the impact of structure-reactivity relationships on kinase selectivity. Finally, data are presented on the PK/PD relationships of acalabrutinib in healthy volunteers. The combined features of acalabrutinib result in a selective and potent BTK inhibitor that appears to be differentiated from ibrutinib and spebrutinib, supporting further clinical development.

Materials and Methods

Biochemical Kinase Assays. BTK and ITK enzyme activity was measured using the immobilized metal ion affinity-based fluorescence polarization (IMAP) assay. BTK enzyme (Millipore, Dundee, UK) or ITK enzyme (Millipore) was diluted to 16 and 34 nM, respectively, in kinase reaction (KR) buffer (10 mM Tris-HCl, 10 mM MgCl₂, 0.01% Tween 20, 0.1% Na₂SO₄, 1 mM dithiothreitol, and 2 mM MnCl₂, pH 7.5). Serial dilutions were log-linear from 1 mM to 31.6 nM of test compounds were made in 100% dimethylsulfoxide (DMSO). The dilutions in DMSO were then diluted 25-fold in KR buffer. Final compound concentrations ranged from 10 μM to 0.316 nM. Test compound (5 μM/well) in KR buffer (final DMSO concentration of 1%) was mixed with 5 μl/well BTK or ITK enzyme (final concentration of 4 and 8 nM for BTK and ITK, respectively). Test compounds and kinase enzyme were preincubated 1 hour at room temperature before the addition of 5 μl/well of 200 nM fluorescein-labeled substrate peptide (Bik/Lyntide substrate; Molecular Devices, Sunnyvale, CA) in KR buffer. The final peptide substrate concentration was 50 nM. The kinase assay was started by adding 5 μl/well of 20 μM ATP in KR buffer (final ATP concentration of 5 μM ATP, Kₐ ATP). After incubation for 2 hours at room temperature, the enzyme reaction was stopped by adding 40 μl/well IMAP Progressive Binding Solution (Molecular Devices), according to the manufacturer’s instructions, using 60% 1× buffer A and 40% 1× buffer B with 800× diluted beads. After 60-minute incubation at room temperature in the dark, the fluorescence polarization signal was read. Fluorescence at 535 nm was measured using parallel and perpendicular filters to determine differences in rotation due to binding of the phosphorylated substrate peptide to the beads. Values were calculated as the percentage of the difference in readout (delta millipolarization) of the controls with and without ATP. IC₅₀ values were determined by curve fitting of the experimental results using Dotmatics software (Dotmatics, Bishop’s Stortford, UK).

Inhibitory activity on TEC was measured using the LanthaScreen assay (Thermo Fisher Scientific, Carlsbad, CA) according to the manufacturer’s protocol, with a final concentration of 1 nM TEC enzyme (Life Technologies, Carlsbad, CA) and 2 nM Eu-anti-His antibody (Invitrogen, Carlsbad, CA). Serial dilutions of test compounds were prepared as described above for the BTK and ITK IMAP assays. Test compounds, TEC enzyme/antibody mix, and Tracer 178 (final concentration of 1 nM; Invitrogen) were mixed and incubated for 2 hours at room temperature in the dark, prior to reading the time-resolved fluorescence energy transfer signal at 615 and 665 nm. A ratio of 665/615 was used to calculate values expressed as the percentage of the difference in readout (S/N) of the controls with and without the tracer. IC₅₀ values were determined by curve fitting of the experimental results using Dotmatics. Kinase activity was measured using the Z-LYTE assay (Thermo Fisher Scientific) for the following: BMX, TXK, EGFR, ERBB2, ERBB4, JAK3, BLK, FGR, FYN, HCK, LCK, LYN, SRC, and YES1. A 10-point dose response was generated with 1 hour incubation of the test compound with the kinase prior to initiation of the kinase reaction by the addition of ATP. The ATP concentration in the assay was Kₐ ATP for the different kinases. IC₅₀ values were determined by curve fitting of the experimental results at Thermo Fisher.

Glutathione Reactivity Assay. For this assay, 765 μl of a 3.32 mM solution of test compound in methanol was added to 765 μl of a 23.5 mM solution of reduced l-glutathione (GSH) in phosphate buffer (pH 7.4). The mixtures were stirred in a water bath held at 37°C. At specific time intervals, 200-μl aliquots were taken and analyzed by reversed-phase high-performance liquid chromatography (Supplemental). Ln[(compound]/[compound]) was plotted against the time in minutes and linear regression analysis was performed with Excel (Microsoft, Redmond, WA). The time point at which 50% of the compound was consumed via reaction with GSH (terminal elimination half-life; t½) was calculated as t½ = Ln(2)/k, where k is the negative of the slope of the linear trend line.

Human Blood Collection and Human Peripheral Blood Mononuclear Cell Isolation. Venous blood was collected in heparin tubes from healthy human volunteers and kept at ambient temperature for no longer than 24 hours. Peripheral blood mononuclear cells (PBMCs) were isolated, this was done using the Histopaque gradient purification method (GE Healthcare, Uppsala, Sweden) and cryopreserved in 90% DMSO plus 10% fetal bovine serum (FBS).

Inhibition of BCR-Induced CD69 Surface Expression in Human B Cells. PBMC Assay. Cryopreserved PBMCs were thawed, washed, and suspended at 2 × 10⁵ cells/well in RPMI plus 10% FBS in 96-well plates. Test compounds were added to PBMCs using a 1/2 log dose titration (final concentration of 10 μM to 0.316 nM) and incubated for 2 hours at 37°C, 5% CO₂. The final DMSO concentration was 0.1%. Goat anti-human immunoglobulin IgM F(ab’/2) (Southern Biotech, Birmingham, AL) was added and cells were incubated for an additional 18 hours. Cells were stained with CD69-fluorescein isothiocyanate (FITC), CD19-BV421, and CD3-BV510 antibodies (BD Biosciences, San Diego, CA) for 30 minutes at 4°C, with 7-aminoactinomycin D (7-AAD) as a viability measure, followed by flow cytometry using a FACSCaliber flow cytometer (BD Biosciences).

Inhibition of BCR-Induced CD69 Surface Expression in Human B cells: Whole blood (WB) Assay. 45 μl blood was diluted 1:1 in RPMI plus 1% FBS and incubated with test compound (as described above). Blood was stimulated with 10 μg/ml mouse anti-human anti-lgD (BD Biosciences) and incubated for 18 hours. Cells were stained with CD69-FITC, CD19-BV421, and CD3-BV510 antibodies (BD Biosciences) for 15 minutes at room temperature, followed by red blood cell lysis with FACS lysing solution (BD Biosciences) in a 96-deep-well plate. Cells were washed with 1 ml/well PBS plus 0.5% bovine serum albumin (BSA), pelleted, and resuspended in 200 μl/well PBS plus 0.5% BSA, followed by flow cytometry. For both PBMC and WB assays, median fluorescence intensity values for CD69 were obtained from the CD19+ CD3− B lymphocyte gate using FCExpress analysis software (De Novo Software, Glendale, CA). EC₅₀ values were determined by curve fitting of the experimental results using Dotmatics.

Murine PD Model. Balb/c mice were dosed via oral gavage with inhibitors or vehicle and then euthanized after 1–24 hours. Extracted spleens were dissociated to obtain single-cell suspensions. Red blood cells were lysed with an ammonium chloride solution (Sigma-Aldrich, Zwijndrecht, the Netherlands). The remaining cells were washed with cold PBS and counted. An aliquot of 1 × 10⁷ cells was snap frozen (LN₂) as cell pellets for subsequent BTK target occupancy enzyme-linked immunosorbent assay (ELISA) and the remainder was used for CD69 analysis (see below).

BTK Target Occupancy ELISA. The percentage of drug-bound BTK in mouse and human samples was determined by an ELISA-based method as follows: OptiPlate 96-well plates (PerkinElmer, Waltham, MA) were coated with 125 ng/well anti-BTK antibody
Splenocytes from drug- and vehicle-treated mice were plated at 10^5 cells/well in 96-well culture plate (MicroWell 96-well microwells; Nunc, Roskilde, Denmark) in Dulbecco’s modified Eagle’s medium F12 plus 10% FBS and incubated overnight at 37°C, 5% CO2. The incubation of each cell lysate with 1 mM dithiothreitol, 0.05% digitonin, and protease inhibitor cocktail (Sigma-Aldrich). Cell lysates were then incubated for 1 hour in the absence or presence of 1 μM acalabrutinib, a saturating concentration that results in complete BTK occupancy. The difference of the signal with excess acalabrutinib represents 100% free BTK (or 0% occupied BTK). The incubation of each cell lysate with 1 mM acalabrutinib represents 0% free BTK (or 100% occupied BTK). The incubation of each cell lysate with 1 μM acalabrutinib was used to correct for background signal not related to free BTK as follows:

\[
\text{% Free BTK Sample } X = \left( \frac{\text{Sample } X - \text{Sample } X' + \text{drug}[1\mu M]}{\text{Day 1 Predose } - \text{Day 1 Predose}' \text{drug}[1\mu M]} \right) \times 100\%
\]

\[
\text{% Occupied BTK = 100% - \text{%Free BTK}}
\]

**Ex Vivo BCR-Induced CD69 Expression in Mouse B Cells.** Splenocytes from drug- and vehicle-treated mice were plated at 2 × 10^5 cells/well in 96-well flat-bottom plates. Goat anti-mouse IgM (10 μg/ml; Southern Biotech) was added and cultures were incubated for 18 hours at 37°C, 5% CO2. Cells were treated with Fe Block (BD Biosciences) and were subsequently stained with CD69-FITC, CD19-BV421, CD3-BV510 (BD Biosciences), and 7-AAD, followed by flow cytometry. Median fluorescent intensity values for CD69 were determined using FCS Express software (DeNovo Software, Glendale, CA). EC50 values were derived by curve fitting of the experimental results using Dotmatics software.

**EGFR Inhibition.** A431 cells were plated at 4 × 10^4 cells/well in a 96-well culture plate (MicroWell 96-well microwells; Nunc, Roskilde, Denmark) in Dulbecco’s modified Eagle’s medium F12 plus 10% FBS and incubated overnight at 37°C, 5%–7% CO2. Serial dilutions (1/2 log) of test compounds were made in 100% DMSO and added to the Jurkat cells (final compound concentration range, 10 μM to 0.316 nM; final concentration of 0.1% DMSO). After 1-hour incubation, Jurkat cells were stimulated with anti-human CD3 and anti-human CD28 (0.1 μg/ml final concentration in the assay; BD Biosciences). The cell culture medium was harvested after 6-hour incubation after activation and was used subsequently to measure IL-2 produced by ELISA (human IL-2 Cytosets; BioSource, Frederick, MD). EC50 values were determined by curve fitting of the experimental results using Domcritics software.

**Jurkat T Cell Assay.** Regulation of anti-CD3/CD28-induced interleukin (IL-2) production on Jurkat T cells was performed using a clone obtained by dilution cloning, with high expression of IL-2 after stimulation (Jurkat J.E6.2.11). Jurkat cells were plated at 2 × 10^5 cells/well in a 96-well culture plate (MicroWell 96-well microwells; Nunc) cultured in Dulbecco’s modified Eagle’s medium F12 plus 10% FBS and then cultured overnight in a cell culture incubator, 37°C, 5%–7% CO2. Serial dilutions (1/2 log) of test compounds were made in 100% DMSO and added to the Jurkat cells (final compound concentration range, 10 μM to 0.316 nM; final concentration of 0.1% DMSO). After 1-hour incubation, Jurkat cells were stimulated with anti-human CD3 and anti-human CD28 (0.1 μg/ml final concentration in the assay; BD Biosciences). The cell culture medium was harvested after 6-hour incubation after activation and was used subsequently to measure IL-2 produced by ELISA (human IL-2 Cytosets; BioSource, Frederick, MD). EC50 values were determined by curve fitting of the experimental results using Domcritics software.

**Human PBMC T Cell Assay.** Cryopreserved PBMCs were thawed, washed, and suspended at 1 × 10^6 cells/well in RPMI plus 10% FBS in 96-well U-bottom polypropylene plates and rested for 1 hour at 37°C, 5% CO2. Cells were then pretreated with a 10-point serial dilution of compounds (as described above for B cell assays). Preincubated PBMCs were transferred to 96-well round-bottom polystyrene plates coated with anti-human CD3 antibody (coated at 1 μg/ml for 2 hours at 37°C, clone UCHT-1; BD Biosciences) or uncoated wells for controls and incubated overnight at 37°C, 5% CO2. PBMCs were washed twice in PBS containing 0.5% BSA and stained with CD4-Alexa Fluor 647 (clone HV-001). The study was performed in accordance with the ethical principles stated in the Declaration of Helsinki, U.S. Food and Drug Administration regulation 21 CFR 312 (parts 50 and 56), and International Conference on Harmonisation guidelines for good clinical practice. All subjects provided informed consent on an institutional review board–approved protocol. Acalabrutinib was administered after an overnight fast and blood samples were collected for PK analysis at predose and at 15 and 30 minutes and 1, 1.5, 2, 3, 4, 6, 8, 12, 13, 14, 15, 16, 18, 20, 24, 36, 48, and 60 hours postdose (±5 minutes). Plasma concentrations of acalabrutinib were determined using a validated analytical liquid chromatography–tandem mass spectrometry method against a stable labeled internal standard at Basi (West Lafayette, IN) in lithium heparin plasma. The quantification range for acalabrutinib was 1–1000 ng/ml.

PK analyses were performed using noncompartmental methods with Phoenix WinNonlin (version 6.3; Pharsight Inc., Mountain View, CA) and GraphPad Prism (version 6.00 for Windows; GraphPad Software Inc., La Jolla, CA) software. The maximum observed plasma concentration (Cmax) and time to reach Cmax (Tmax) were taken directly from the individual’s data. The following PK parameters were derived from the plasma concentrations of acalabrutinib: area under the concentration-time curve (AUC) from time 0 to last quantifiable concentration (AUClast), AUC from time 0 to ∞ (AUC∞), Cmax, Tmax, t1/2, and terminal elimination rate constant (α). AUC0–12, AUC0–24, and AUC0–∞ (where data permitted) were calculated using the linear trapezoidal method (log/linear) as. As data permitted, AUC
was calculated as the negative of the slope of the terminal log-linear segment of the plasma concentration-time curve. $t_{1/2}$ was calculated according to the following equation: $t_{1/2} = 0.693/\lambda z$. Oral clearance (CL/F) and volume of distribution (Vz/F) were calculated as follows: 

$$\text{CL/F} = \frac{\text{dose}}{\text{AUC}_0}$$ and 

$$\text{Vz/F} = \frac{\text{Dose}}{\lambda z \times \text{AUC}_0}.$$ 

### Results

**On-Target Biochemical and Functional Characterization and Modeling of BTK Inhibitor Interactions.**

Acalabrutinib (compound 1) displayed low nanomolar inhibition in the IMAP assay with an IC$_{50}$ value of 5.1 nM. In a head-to-head comparison in the same biochemical assay, ibrutinib (compound 2) had a potency (as measured by IC$_{50}$) of 1.5 nM, whereas the potency of spebrutinib (compound 3) was 2.3 nM (Fig. 2). However, the inhibitory potential of spebrutinib was lower in BCR-mediated cell surface expression of CD69 in PBMCs and in the human whole blood (hWB) assay. In the latter assay, acalabrutinib (EC$_{50}$ = 9.2 ± 4.4 nM) and ibrutinib (EC$_{50}$ = 5.8 ± 3.0 nM) showed no statistically significant difference, whereas spebrutinib was less potent (EC$_{50}$ = 140 nM). Inversion of the stereochemistry of acalabrutinib had a profound effect on the inhibitory potency of BTK, as demonstrated by the approximately 130-fold loss in the IMAP assay. The cell-based EC$_{50}$ values of the R-enantiomer (compound 4) were consistent with this observation as well (592 and 1530 nM in the PBMC and hWB assays, respectively).
Figure 1 shows a model of the acalabrutinib/BTK complex that was created by docking acalabrutinib into the ATP pocket of BTK using a co-crystal structure of a reversible inhibitor/BTK complex (Protein Data Bank entry 3GEN). The model included minimization of two amino acid residues to accommodate the back-pocket filling substituent of acalabrutinib (Met449 and Leu542). This model indicates that H-bonding capabilities of the central 8-aminoimidazopyrazine moiety with Met477 and Glu475 in the hinge region are present. The 2-pyridylbenzamide shows hydrogen bonding interactions with Ser538 and Asp539.

The importance of the 2-pyridyl nitrogen was further elucidated by profiling compounds in which the 2-pyridyl nitrogen is moved to positions 3 and 4, respectively. Compounds containing 3-pyridyl (compound 5) and 4-pyridyl (compound 6) moieties were 840- and 360-fold less potent than acalabrutinib in the biochemical assay. Absence of activity was confirmed in peripheral B cells in functional assays using human PBMCs and hWB, with EC\textsubscript{50} > 4 \mu M for both compounds (Fig. 2). Data generated on additional compounds highlight the relevance of the positioning of the H-bonding partners when the amide as generated on additional compounds highlight the relevance of the contribution of affinity and inactivation rate, preserving potency for BTK.

To further substantiate whether the relative reactivity of the electrophilic moieties could impact the BTK potency and the overall kinase selectivity profile, the inhibitors were reacted with GSH in a semiphasiological setting. Acalabrutinib has a butynamide moiety, which contributes to a slower conversion of the parent, with a $t_{1/2}$ of 5.5 hours (Fig. 2). In contrast, the acrylamide-containing compounds ibrutinib and spebrutinib were more rapidly consumed than acalabrutinib, with average $t_{1/2}$ values of 2 and 1 hours, respectively. Intriguingly, compound 7 displayed a much faster turnover than acrylamides ibrutinib and spebrutinib. The closer proximity of the electrophile in compound 7 to the electron-deficient central heteroaryl imidazoypyrazine moiety could augment the electrophilicity and may explain the lower $t_{1/2}$ average of 0.6 hours. Methyl compounds 8 and 9 lose the capacity to react with GSH, which suggests that the degree of BTK inhibition observed could be due to reversible binding (Fig. 2). The observation that compound 8 still displayed some residual activity suggests that steric hindrance in proximity of Cys481 impacts the binding potential, rather than the relative electrophilicity of the reactive group per se.

Profiling of the clinical BTK inhibitors and compound 7 on the cysteine kinase panel distinguishes acalabrutinib from the acrylamide compounds in terms of selectivity. All kinases with an Asp in the i+3 position were not sensitive to acalabrutinib, and the inhibition of TEC, BMX, and TXK kinases was lower than for any of the acrylamide compounds. A direct comparison of the IC\textsubscript{50} values of acalabrutinib and acrylamide-containing compound 7 revealed the influence of the warhead choice on the cysteine kinase selectivity profile (Table 2). In this data set, ERBB4 is an outlier, as this is the only kinase that has a glutamate (Glu) in the i+3 position. Although the predicted cysteine pKa is on par with Asp kinases, the tested compounds acalabrutinib, ibrutinib, spebrutinib, and acrylamide compound 7 all displayed a single- or double-digit nanomolar inhibition in the biochemical assay for ERBB4. Since spebrutinib was comparatively fairly reactive, yet the least potent on ERBB4 (IC\textsubscript{50} = 49 nM), the inhibition of ERBB4 may be governed to a lesser extent by the electrophilic nature of the reactive moiety. Each of the clinical BTK inhibitors was also profiled at 1 \mu M in a competition binding assay on a panel of 456 human kinases (KINOMEscan at Thermo Fisher using the Z-LYTE assay. TEC kinase activity was determined in a LanthaScreen assay. Results are mean ± S.D. of at least three independent experiments.

<table>
<thead>
<tr>
<th>Kinase</th>
<th>i+3 Residue</th>
<th>IC\textsubscript{50}</th>
</tr>
</thead>
<tbody>
<tr>
<td>BTK</td>
<td>Asn</td>
<td>5.1 ± 1.0</td>
</tr>
<tr>
<td>TEC</td>
<td>Asn</td>
<td>126 ± 11</td>
</tr>
<tr>
<td>ITK</td>
<td>Asp</td>
<td>&gt;1000</td>
</tr>
<tr>
<td>BMX</td>
<td>Asn</td>
<td>46 ± 12</td>
</tr>
<tr>
<td>TXK</td>
<td>Asn</td>
<td>368 ± 141</td>
</tr>
<tr>
<td>EGF\textsubscript{R}</td>
<td>Asp</td>
<td>&gt;1000</td>
</tr>
<tr>
<td>ERBB\textsubscript{2}</td>
<td>Asp</td>
<td>~1000</td>
</tr>
<tr>
<td>ERBB\textsubscript{4}</td>
<td>Glu</td>
<td>16 ± 5</td>
</tr>
<tr>
<td>BLK</td>
<td>Asp</td>
<td>&gt;1000</td>
</tr>
<tr>
<td>JAK3</td>
<td>Asp</td>
<td>&gt;1000</td>
</tr>
</tbody>
</table>

TABLE 2  
IC\textsubscript{50} determination on cysteine kinases with a cysteine in the same position as Cys481 in BTK
Of these kinases, 395 are non-mutant protein kinases. Our results demonstrate that acalabrutinib is the most selective BTK inhibitor of the three compounds profiled (Fig. 3). For acalabrutinib, only 1.5% of the nonmutant protein kinases were inhibited $\geq 65\%$ at 1 $\mu$M. For ibrutinib and spebrutinib, 8.9% and 7.6%, respectively, of the nonmutant protein kinases were inhibited $\geq 65\%$ at 1 $\mu$M. Interestingly, strong inhibition by ibrutinib was observed for all kinases belonging to the SRC-family kinases, which is in line with earlier published results (Honigberg et al., 2010) and our own data (Byrd et al., 2016). Spebrutinib showed a more scattered inhibition over the kinase phylogenetic tree. Evaluation of SRC-family kinase inhibition confirmed that acalabrutinib did not inhibit any member (IC$_{50}$ values all exceeding 1 $\mu$M), whereas ibrutinib demonstrated single- or double-digit nanomolar inhibition on all members tested (Supplemental Table 4).

**Off-Target Cellular Activities of BTK Inhibitors.** The functional relevance of the differences in the observed biochemical inhibition of non-BTK kinases by acalabrutinib, ibrutinib, spebrutinib, and compound 7 was explored in specific cell lines. EGFR inhibition of selected BTK inhibitors was tested in two EGFR-expressing human tumor cell lines: an epidermoid carcinoma (A431) cell line (Table 3) and a bladder carcinoma (HT-1376) cell line (Supplemental Fig. 1). Both cell lines gave similar EC$_{50}$ values for the tested compounds on EGF-induced EGFR phosphorylation. Acalabrutinib showed no or only minimal inhibition up to a concentration of 10 $\mu$M. Results with compound 7 suggest that this is due to the electrophile switch from acrylamide to butynamide. Spebrutinib inhibited EGF-induced EGFR phosphorylation with an EC$_{50}$ of 4.7 $\mu$M, which suggests that the reactivity of electrophile is not the only parameter relevant for kinase selectivity. Ibrutinib inhibited...
Acalabrutinib: A Differentiated Covalent BTK Inhibitor

were used directly in the BTK target occupancy assay (Fig. 4C). Acalabrutinib and ibrutinib showed (near) complete BTK occupancy along with complete inhibition of anti-IgM–induced CD69 expression on splenocyte B cells for the 3-hour postdose time point. These results are in line with the dose–response data showing full inhibition of splenocyte B cells at oral doses \( \geq 10 \) mg/kg for acalabrutinib and ibrutinib, 3 hours after dosing. Additional experiments demonstrated that complete BTK target occupancy and full B cell deactivation was already achieved 1 hour after dosing (data not shown). In contrast, a 25-mg/kg dose of spebrutinib showed incomplete BTK target occupancy (approximately 15% free BTK versus vehicle control) and inhibition of anti-IgM–induced CD69 expression on peripheral B cells (approximately 25% remaining activity versus vehicle control). This again corresponded with the observed higher ED\(_{50}\) of 20 mg/kg for this BTK inhibitor. Over time, an increase in the amount of free BTK and an increase in splenocyte B cell function was demonstrated, as measured by function of anti-IgM–induced CD69 expression. However, BTK target occupancy and inhibition of B cell function was still observed 24 hours postdose. Acalabrutinib and ibrutinib displayed around 35% free BTK and 40% B cell activity versus vehicle control at 24 hours postdose, whereas approximately 55% free BTK and 75% splenocyte B cell activity was observed for spebrutinib at this time point. The average return rate for all three BTK inhibitors was estimated using linear fitting of the data for the return of B cell function (anti-IgM–induced CD69 expression on splenocyte B cells) and the return of free BTK. These return rates were 2.0% ± 0.2% and 1.7% ± 0.1% per hour, respectively.

**PK/PD in Healthy Volunteers.** The PK properties and safety of acalabrutinib were evaluated in a sequential dose-escalation study in healthy adult volunteers (six per group) after oral administration of two doses of 2.5, 5, 25, or 50 mg given 12 hours apart on a single day and a single dose of either 75 or 100 mg. Acalabrutinib was rapidly absorbed, with median time to maximum plasma concentration (\( T_{\text{max}} \)) values between 0.5 and 1.0 hours for all dose cohorts, independent of dose level (Supplemental Fig. 2; Supplemental Table 5). The increase in mean \( C_{\text{max}} \) was greater than dose proportional from 5 to 25 mg. However, between 2.5–5.0, 25–50, and 50–100 mg, the increases in mean \( C_{\text{max}} \) were close to dose proportional. The mean values of AUC\(_{0-12h}\), AUC\(_{0-24h}\), and AUC\(_{0-\infty}\) increased in a dose-proportional manner based on the increases of the total dose administered (Fig. 5A). Linear regression analysis of the natural log (ln) transformed AUC\(_{0-24h}\) and AUC\(_{0-\infty}\) relative to the ln transformed dose administered, indicated that the increases in AUC relative to the increases in dose administered were linear. Rapid elimination was observed, with mean \( t_{1/2} \) values ranging from 0.88 to 2.1 hours in cohorts 1–5. The mean calculated CL/F values ranged from 165 to 219 l/h and appeared to be independent of the dose administered. Vz/F values ranged from 233 to 612 liters and also appeared to be independent of the dose administered.

Of 59 enrolled subjects, 16 (27%) reported one or more adverse events during the study. All adverse events were grade 1 or 2. No serious adverse events occurred in the study. Of the adverse events reported, three (constipation, somnolence, and feeling cold) were assessed as related to acalabrutinib. No study drug–related adverse events led to discontinuation from the study. No effect of acalabrutinib was observed on any laboratory parameters (i.e., hematology, serum chemistry, urinalysis, cardiac troponin I, and C-reactive protein). No effect was
Fig. 4. (A) In vivo potency. Mice (five per group) were given an oral dose of acalabrutinib, ibrutinib, spebrutinib, or vehicle over a concentration range (x-axis). After 3 hours, spleens were extracted and splenocytes were stimulated with anti-IgM for 18 hours, followed by CD69 expression analysis by flow cytometry gated on CD19+ B cells. The CD69 median fluorescent intensity values were normalized as a percentage of the vehicle control group and the mean average and S.E.M. were plotted for all mice in each dose cohort. (B) Return of function. Mice (five per group) received a single oral 25 mg/kg dose of acalabrutinib, ibrutinib, spebrutinib, or vehicle. Spleens were extracted 3, 6, 12, 18, or 24 hours after dosing and single-cell suspensions were made. Splenocytes were immediately cultured with anti-IgM for 18 hours, followed by CD69 surface expression measurement by flow cytometry as in (A). Data show CD69 expression for each mouse normalized as a percentage of the vehicle control group. Data presented are expansions from Herman et al. (2017). (C) BTK target occupancy was measured in the mouse splenocyte samples from the experiment described in (B). (D) Structure of the target occupancy probe ACP-4016 (compound 10). Cmpd, compound.
observed of acalabrutinib on physical examinations, vital signs, or electrocardiography parameters.

The PD of acalabrutinib was evaluated using the BTK occupancy assay and measuring the inhibition of CD69 expression on B cells after ex vivo BCR stimulation. Both PD readouts were dose dependent, with a plateau observed at the 75- and 100-mg dose levels, 3 hours after acalabrutinib administration. At this time point, the degree of BTK median occupancy was around 99% for the 75- and 100-mg doses (Fig. 5B). This correlated with near complete inhibition for CD69 (Fig. 5C) for the same doses and time point. However, only the 100-mg cohort maintained high BTK median occupancy and high BCR functional inhibition over time (Fig. 5D). At 12 hours, the median occupancy was 99% and the median CD69 inhibition was 95%, whereas these parameters were 90% and 84% at 24 hours, respectively. CD86 expression levels were also determined in parallel and essentially matched the inhibition of CD69 expression (data not shown).

**Discussion**

Acalabrutinib was identified as a BTK inhibitor with a differentiated kinase selectivity profile compared with other BTK inhibitors in development. Key structural components of acalabrutinib include a 2-pyridylbenzamide moiety and the electrophilic 2-butynamide moiety that is involved in covalent binding to Cys481. The proximal positioning of the 2-butynamide moiety to the electron-deficient (and thus electron-withdrawing) imidazopyrazine core may help to reactivate this otherwise
fairly inert functionality. The potency difference of the enantiomeric pair (compare acalabrutinib and compound 4) showed that the activity primarily resides in the S-enantiomer, suggesting better positioning of the butynamide moiety. As demonstrated in the GSH assay, acalabrutinib displayed lower reactivity than acrylamides ibrutinib, spebrutinib, and compound 7. This may help to minimize inhibition of off-target cysteine kinases that exhibit higher cysteine pKa values than that for Cys481 in BTK. Indeed, acalabrutinib is the most selective with regard to inhibition of TEC-, EGFR-, and SRC-family kinases. The correlation of biochemical off-target inhibition and functional consequences in selected cell lines was confirmed for different kinases.

Inhibitors of the EGFR signaling pathway cause skin rash and diarrhea, and these toxicities are believed to be "class effects" (Lynch et al., 2007; Dy and Adjei, 2013). With respect to the inhibitory potential for EGFR, the rank order of compounds was identical in biochemical and cellular settings, with acalabrutinib showing a lack of functional inhibitory effects (EC50 > 10 μM). The events of diarrhea reported during acalabrutinib treatment of patients with CLL (grades 1 to 2, 38%; all grades, 39%) have been generally mild (Byrd et al., 2016). Given the observed exposure levels of acalabrutinib after a single oral dose of 100 mg (580 ± 150 ng/ml) and the absence of effects on phospho-EGFR inhibition in two relevant cell lines at these concentrations, we do not expect to see EGFR-mediated adverse events for acalabrutinib.

ITK signaling in Jurkat cells and in primary human peripheral T cells correlated with the biochemical IMAP data. The drug concentrations needed to inhibit IL-2 production in Jurkat cells and modulation of human peripheral T cells may well be achieved in patients treated with ibrutinib or spebrutinib (Dubovsky et al., 2013; Evans et al., 2013) and therefore may bear physiologic relevance. Indeed, ibrutinib is a reported irreversible covalent ITK inhibitor with confirmed occupancy on this kinase in patients with CLL (Dubovsky et al., 2013). Treatment with ibrutinib reduced the number of Th17 T cells as a percentage of the total T cell population in patients with CLL, as well as Th17 development from mouse naive CD4+ T cells. The mouse observations are in line with data reported for ITK−/− mice, in which a shift in the balance from Th17 to regulatory T cells was observed (Gomez-Rodriguez et al., 2014). The same authors reported that this effect is even more pronounced in ITK/ITK−/− mice (Gomez-Rodriguez et al., 2011), indicating redundancy between ITK and TXK. Since ibrutinib inhibited both ITK and TXK in the low nanomolar range in the biochemical assays, the effects of ibrutinib on T cell differentiation most likely mimic the double-knockout phenotype. ITK is also expressed in natural killer (NK) cells (Khurana et al., 2007), and inhibition thereof has been reported to decrease the antibody-dependent cellular cytotoxicity function of NK cells (Kohrt et al., 2014). It was reported that ibrutinib inhibited both rituximab- and trastuzumab-induced NK cell cytokine secretion and lysis in vitro in a dose-dependent manner (0.1 and 1 μM), whereas acalabrutinib did not show any effects at 1 μM (Rajasekaran et al., 2014). This indicates that acalabrutinib is associated with a reduced risk of affecting antibody-dependent cellular cytotoxicity–mediated therapies.

An increased incidence in severe hemorrhage was reported in patients treated with ibrutinib and has been attributed to the effect of ibrutinib on several distinct signaling pathways (Byrd et al., 2015; Wang et al., 2015; Shatzel et al., 2017). Therefore, patients receiving ibrutinib are monitored to reduce the potential risk for bleeding. Although the role of BTK on collagen-induced platelet aggregation has been well described, there is no general increase of bleeding risk in patients with X-linked agammaglobulinemia lacking functional BTK (Quek et al., 1998; Winkelstein et al., 2006), suggesting that BTK inhibition alone is likely not responsible for increased bleeding risk. In platelets, the downstream signaling of several receptors on platelets, including the platelet collagen receptor glycoprotein VI and C-type lectin-like receptor 2, is mediated by BTK and TEC (Shatzel et al., 2017). Earlier, we reported on differences in platelet aggregation using platelets from patients treated with acalabrutinib or ibrutinib (Byrd et al., 2016). In an in vivo thrombus formation model, diminished platelet reactivity was observed in samples from patients treated with ibrutinib, whereas platelets from acalabrutinib-treated patients showed similar reactivity to those derived from non-treated healthy controls. Because TEC kinase phosphorylation is highly dependent on platelet aggregation (Hamazaki et al., 1998; Atkinson et al., 2003), the level of TEC inhibition may govern the bleeding risk. The relative biochemical IC50 values for TEC of acalabrutinib (126 nM) and ibrutinib (10 nM) may well contribute to the observed differences in the above model. In addition, inhibition of SRC-family kinases by ibrutinib may play a role in the observed bleeding incidence in ibrutinib-treated patients through modulation of fibrinogen- and von Willebrand factor–induced platelet activation (Séverin et al., 2012; Senis et al., 2014). Regulation of SRC-mediated platelet activation may be anticipated at exposure levels observed in patients that are treated with ibrutinib. For instance, Patel et al. (2017) reported that ibrutinib demonstrated potent inhibition of phosphorylation of SRC family members LCK and SRC in T cells, with an EC50 of <0.2 μM, whereas the EC50 for acalabrutinib was not reached at 10 μM. Again, these data correspond well with the nanomolar inhibition by ibrutinib for both SRC and LCK. Taken together, these observations indicate that effects of ibrutinib on bleeding could be multifactorial. The improved selectivity profile of acalabrutinib for BTK versus TEC and SRC-family kinases may prove advantageous in this regard.

Overall, the biochemical potency of all compounds tested for BTK activity traced well with the inhibitory potential of marker CD69 in our PBMC and hWB assays, except for spebrutinib. For instance, the potency of BTK-mediated inhibition of peripheral B cell function in hWB was approximately 15-fold lower for spebrutinib than for acalabrutinib and ibrutinib. This suggests that plasma proteins or other components of hWB (e.g., red blood cells, platelets, or neutrophils) may contribute to a lower free fraction of spebrutinib that is available for BTK inhibition. The in vivo potency data generated in the mouse PD model mirrored the cellular data generated, except that acalabrutinib showed better potency than ibrutinib in vivo. With spebrutinib, efficacy could be obtained at higher dosages, but potency was inferior to acalabrutinib and ibrutinib. Evaluation of return of free BTK and return of B cell function in mice demonstrated that the return rate is independent of the type of BTK inhibitor tested. Hence, the de novo synthesis rate of BTK is the primary driver for the loss of PD effect in a single dose setting.
Acalabrutinib: A Differentiated Covalent BTK Inhibitor

Authorship Contributions

Participated in research design: Barf, Covey, Izumi, Gulrajani, Mittag, Pearson, Ulrich, Kaptein.
Conducted experiments: Barf, van der Kar, Gulrajani, van Lith, van Hoek, de Zwart, Mittag, Demont, Verkaik, Krantz.

Performed data analysis: Barf, Covey, Izumi, van der Kar, Gulrajani, van Lith, van Hoek, de Zwart, Mittag, Demont, Verkaik, Krantz, Pearson, Kaptein.

Wrote or contributed to the writing of the manuscript: Barf, Covey, Izumi, Pearson, Kaptein.

References

Grenningloh R (2016) Discovery of the highly specific BTK inhibitor M2951 and pharmacodynamic modeling of BTK occupancy versus efficacy in RA and SLE models. 14th Annual Discovery on Target; 2016 Sep 19–22; Boston, MA.

In human healthy subjects, acalabrutinib is an orally bioavailable BTK inhibitor with fast absorption, dose-proportional PK, and a short half-life in the systemic circulation. Despite the short half-life, acalabrutinib had a pronounced on-target impact in peripheral blood B cells that was dose dependent. Complete BTK occupancy was observed 3 and 12 hours after a single 100-mg dose, indicating that a saturating concentration was achieved that resulted in near complete inhibition of a BCR-induced functional response (i.e., CD69 expression). Both measures remained high for 24 hours. Therefore, covalent modification of BTK by acalabrutinib prolonged target occupancy and PD that extend beyond the relatively short plasma half-life in healthy volunteers. In patient populations with more rapidly proliferating B cells, we anticipate an increased de novo synthesis rate of BTK, suggesting that more frequent dosing may be required to achieve optimal BTK inhibition. Indeed, a 100-mg twice-daily dose in patients with CLL showed a higher median BTK occupancy, with less variability at trough, than the 100- and 250-mg/d cohorts (Byrd et al., 2016). This illustrates that maximal target coverage can be achieved with twice-daily dosing, which we believe is advantageous for optimal treatment across patient populations with B cell malignancies.

In conclusion, monitoring structure-reactivity relationships may help to mitigate the risk for off-target adverse events related to reactivity of the electrophile (Barf and Kaptein, 2012). Low electrophilicity is an important feature to consider to progress the most suitable covalent inhibitor candidates through the pipeline. The use of a straightforward GSH assay to assess the likelihood and the kinetics of covalent binding revealed a difference in reactivity between compounds containing butyramide and acrylamide moieties. We believe that the lower electrophilicity of acalabrutinib along with the higher nucleophilicity of Cys481 in BTK contributes to the observed selectivity profile, which may reduce off-target mediated adverse events. In combination with the improved in vivo potency, acalabrutinib appears to have a differentiated preclinical profile from ibrutinib and spebrutinib. Selective covalent BTK probe 10 helped to confirm the correlation of the degree of BTK occupancy and engagement by acalabrutinib in preclinical and clinical settings. Acalabrutinib is a rapidly absorbed covalent BTK inhibitor with a short half-life, yet it reaches full target occupancy at a single oral dose of 100 mg in healthy human subjects. Clinical evaluation of acalabrutinib in multiple B cell malignancies, solid tumors, and selected autoimmune indications is currently in progress.

Acknowledgments

The authors thank Anouk de Jong for performing the PBMC T cell assays, Tim Ingallinera for preparing the in vivo formulations for the mouse PD experiments, Gerjan de Bruin for analysis of the K_i and k_{mae} data, and Greg Slatter for the discussion on the human PK/PD data. BioAxis Research BV is acknowledged for the pH_{50} modeling of kinase activities. Final versions of the figures were created by Cognition Studios. This article reflects the reviews of the authors on some of the research and data regarding acalabrutinib. This research has spanned many years and is ongoing. This article does not attempt to address exhaustively every aspect and detail of that research. All authors are employees of or consultants to and are shareholders of Acerta Pharma BV.


Address correspondence to: Tjeerd Barf, Acerta Pharma BV, Kloosterstraat 9, 5349 AB Oss, The Netherlands. E-mail: t.barf@acerta-pharma.com